Flossbach Von Storch AG Boosts Stock Position in BioNTech SE (NASDAQ:BNTX)

Flossbach Von Storch AG lifted its position in BioNTech SE (NASDAQ:BNTX) by 1.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,548,660 shares of the company’s stock after purchasing an additional 35,445 shares during the quarter. BioNTech comprises 1.7% of Flossbach Von Storch AG’s holdings, making the stock its 19th largest position. Flossbach Von Storch AG owned approximately 1.49% of BioNTech worth $374,526,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of BNTX. State of Wyoming purchased a new position in shares of BioNTech during the 2nd quarter valued at about $26,000. Covestor Ltd acquired a new position in BioNTech in the third quarter valued at approximately $32,000. Eagle Bay Advisors LLC purchased a new stake in BioNTech in the 2nd quarter worth approximately $33,000. Resurgent Financial Advisors LLC acquired a new stake in shares of BioNTech during the 4th quarter worth approximately $47,000. Finally, UMB Bank n.a. purchased a new position in shares of BioNTech during the 4th quarter valued at approximately $50,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on BNTX. UBS Group dropped their price target on shares of BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 27th. Oppenheimer assumed coverage on BioNTech in a report on Friday, January 5th. They issued a “market perform” rating for the company. BMO Capital Markets lowered their price target on BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a research report on Thursday, March 21st. The Goldman Sachs Group cut their price objective on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $107.00 target price on shares of BioNTech in a research report on Wednesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, BioNTech currently has a consensus rating of “Hold” and a consensus price target of $120.40.

BioNTech Price Performance

Shares of BioNTech stock traded up $0.06 during trading hours on Wednesday, reaching $86.40. 1,264,662 shares of the company’s stock were exchanged, compared to its average volume of 671,486. The business has a fifty day moving average of $91.49 and a two-hundred day moving average of $97.57. The company has a market capitalization of $20.54 billion, a P/E ratio of 20.97 and a beta of 0.23. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. BioNTech SE has a 1 year low of $85.21 and a 1 year high of $125.83.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. As a group, research analysts predict that BioNTech SE will post -1.67 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.